Explore › Intervention › Lispro insulin in parenteral dosage form
Intervention

Lispro insulin in parenteral dosage form

Also known as: Insulin lispro-containing product in parenteral dose form Lispro insulin in parenteral dosage form Lispro insulin-containing product in parenteral dose form Product containing insulin lispro in parenteral dose form (medicinal product form) Product containing lispro insulin in parenteral dosage form Product containing lispro insulin in parenteral dosage form (medicinal product form) Product containing lispro insulin in parenteral dose form (medicinal product form) insulin in combination with oral diabetes medications (insulin+metformin or insulin+metformin+sulfonylureas, >=75% of year before each landmark)
3 findings 1 paper 4 related entities View in graph →

Related entities

conditions
Metastatic hepatocellular carcinoma1
outcomes
Hepatocellular carcinoma1
populations
Type 2 Diabetes Patients1
studys
PMC91075291

Findings (27)

None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →

Papers (1)